Peeters Protides of the Biological Fluids

Proceedings of the Thirty-Fifth Colloquium, 1987
1. Auflage 2013
ISBN: 978-1-4831-4838-0
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 556 Seiten, Web PDF

Protides of the Biological Fluids examines protides of the biological fluids and covers topics ranging from the use of DNA probes to diagnose inherited diseases and receptors to the conformation and function of biologically active peptides. This text has 115 chapters and begins by demonstrating the existence of gene families common to several vertebrates and which evolved by intragenic duplication. The chapters that follow focus on the use of DNA probes in the analysis of inherited disorders such as thalassemia and hemophilia. The reader is then introduced to receptors, especially for peptides. Receptors on circulating cells, hormone receptors, receptors involved in cancer, and immunoglobulin receptors are explored. The section on the conformation and function of biologically active peptides considers the methods including spectroscopic methods, crystallography, and theoretical conformational analysis. In particular, the use of synchrotron X-radiation in biological crystallography and of 2D NMR spectroscopy in the identification of folded structures in immunogenic peptides is highlighted. This book will be of value to biologists and biochemists.

Autoren/Hrsg.

Peeters, H.

Inhaltsverzeichnis

1;Front Cover
;1
2;Protides of the Biological Fluids;4
3;Copyright Page;5
4;Table of Contents;6
5;PREFACE;18
6;ACKNOWLEDGEMENTS;20
7;Part 1. The Sixteenth Arne Tiselius Memorial Lecture;22
7.1;CHAPTER 1. EXPRESSION OF GENES ENCODING THE VITAMIN D BINDING PROTEIN AND TRANSFERRIN;24
7.1.1;INTRODUCTION;24
7.1.2;ACKNOWLEDGEMENTS;31
7.1.3;REFERENCES;31
7.2;SECTION A: DNA Probes for Inherited Diseases;34
7.2.1;CHAPTER 2. DIAGNOSIS OF THALASSEMIA BY DNA ANALYSIS;36
7.2.1.1;ABSTRACT;36
7.2.1.2;KEYWORDS;36
7.2.1.3;INTRODUCTION;36
7.2.1.4;DIRECT DETECTION OF THE MUTATION;37
7.2.1.5;INDIRECT METHOD;39
7.2.1.6;DNA AMPLIFICATION;39
7.2.1.7;CONCLUSION;40
7.2.1.8;REFERENCES;40
7.2.2;CHAPTER 3. FIRST TRIMESTER PRENATAL DIAGNOSIS OF HEMOPHILIA A BY COMBINED USE OF DNA PROBES;42
7.2.2.1;ABSTRACT;42
7.2.2.2;KEYWORDS;42
7.2.2.3;INTRODUCTION;42
7.2.2.4;MATERIALS AND METHODS;43
7.2.2.5;RESULTS;43
7.2.2.6;CONCLUSIONS;44
7.2.2.7;ACKNOWLEDGEMENTS;44
7.2.2.8;REFERENCES;44
7.2.3;CHAPTER 4. CARRIER DETECTION AND GENETIC COUNSELLING IN HEMOPHILIA USING DNA PROBES;46
7.2.3.1;ABSTRACT;46
7.2.3.2;KEYWORDS;46
7.2.3.3;INTRODUCTION;46
7.2.3.4;MATERIALS AND METHODS;46
7.2.3.5;RESULTS AND DISCUSSION;49
7.2.3.6;ACKNOWLEDGEMENTS;49
7.2.3.7;REFERENCES;49
7.2.4;CHAPTER 5. THE IDENTIFICATION OF HAEMOPHILIA B MUTATIONS;50
7.2.4.1;ACKNOWLEDGEMENTS;53
7.2.4.2;REFERENCES;53
7.2.5;CHAPTER 6. GENE DEFECTS IN HAEMOPHILIA A AND B;54
7.2.5.1;ABSTRACT;54
7.2.5.2;KEYWORDS;54
7.2.5.3;HAEMOPHILIA B: FACTOR IX DEFICIENCY;54
7.2.5.4;HAEMOPHILIA A: FACTOR VIII DEFICIENCY;55
7.2.5.5;REFERENCES;55
7.2.6;CHAPTER 7. CARRIER DETECTION USING DNA ANALYSIS IN FRENCH FAMILIES OF HAEMOPHILIA A AND B;58
7.2.6.1;ABSTACT;58
7.2.6.2;KEYWORDS;58
7.2.6.3;INTRODUCTION;58
7.2.6.4;MATERIALS AND METHODS;58
7.2.6.5;RESULTS AND DISCUSSION;58
7.2.6.6;ACKNOWLEDGEMENTS;60
7.2.6.7;REFERENCES;60
7.2.7;CHAPTER 8. STUDIES ON THE MOLECULAR BASIS OF STEROID SULPHATASE DEFICIENCY IN MAN;62
7.2.7.1;ABSTRACT;62
7.2.7.2;KEYWORDS;62
7.2.7.3;INTRODUCTION;62
7.2.7.4;PATIENTS AND METHODS;63
7.2.7.5;RESULTS;63
7.2.7.6;CONCLUSION;64
7.2.7.7;ACKNOWLEDGEMENTS;64
7.2.7.8;REFERENCES;65
7.2.8;CHAPTER 9. MITOTIC-ORIGIN OF A DUCHENNE MUSCULAR DYSTROPHY MUTATION;66
7.2.8.1;ABSTRACT;66
7.2.8.2;KEYWORDS;66
7.2.8.3;INTRODUCTION;66
7.2.8.4;MATERIALS AND METHODS;67
7.2.8.5;RESULTS;67
7.2.8.6;DISCUSSION;70
7.2.8.7;ACKNOWLEDGEMENT;70
7.2.8.8;REFERENCES;70
7.2.9;CHAPTER 10. PROGRESS TOWARDS CLONING OF THE CYSTIC FIBROSIS GENE — IDENTIFICATION OF NEW DNA MARKERS IN THE 7Q31 REGION;72
7.2.9.1;ABSTRACT;72
7.2.9.2;KEYWORDS;72
7.2.9.3;INTRODUCTION;72
7.2.9.4;MATERIALS AND METHODS;72
7.2.9.5;RESULTS;73
7.2.9.6;DISCUSSION;74
7.2.9.7;ACKNOWLEDGEMENTS;74
7.2.9.8;REFERENCES;74
7.2.10;CHAPTER 11. DNA MARKER ANALYSIS OF DANISH POLYCYSTIC KIDNEY DISEASE FAMILIES;76
7.2.10.1;ABSTRACT;76
7.2.10.2;KEYWORDS;76
7.2.10.3;INTRODUCTION;76
7.2.10.4;MATERIALS AND METHODS;77
7.2.10.5;RESULTS;77
7.2.10.6;DISCUSSION;78
7.2.10.7;ACKNOWLEDGMENTS;78
7.2.10.8;REFERENCES;78
7.2.11;CHAPTER 12. INFORMATION GIVEN BY THE 3'HVR -GLOBIN MARKER IN TEN FRENCH FAMILIES WITH ADULT POLYCYSTIC KIDNEY DISEASE;80
7.2.11.1;ABSTRACT;80
7.2.11.2;KEYWORDS;80
7.2.11.3;INTRODUCTION;80
7.2.11.4;MATERIAL AND METHODS;81
7.2.11.5;RESULTS AND DISCUSSION;81
7.2.11.6;ACKNOWLEDGEMENTS;82
7.2.11.7;REFERENCES;82
7.2.12;CHAPTER 13. USE OF A GENETIC MARKER FOR THE DIAGNOSIS OF ADULT POLYCYSTIC KIDNEY DISEASE IN NORTHERN ITALY;84
7.2.12.1;ABSTRACT;84
7.2.12.2;KEYWORDS;84
7.2.12.3;INTRODUCTION;84
7.2.12.4;MATERIALS AND METHODS;84
7.2.12.5;RESULTS;85
7.2.12.6;DISCUSSION;87
7.2.12.7;REFERENCES;87
7.2.12.8;AKNOWLEDGEMENTS;87
7.2.13;CHAPTER 14. CONSTRUCTION OF LAMBDA GT 11 cDNA LIBRARIES FROM POST-MORTEM HUMAN BRAINS;88
7.2.13.1;ABSTRACT;88
7.2.13.2;KEY WORDS;88
7.2.13.3;INTRODUCTION;88
7.2.13.4;MATERIAL AND METHODS;89
7.2.13.5;RESULTS;89
7.2.13.6;DISCUSSION;90
7.2.13.7;REFERENCES;91
7.2.14;CHAPTER 15. GENETIC ANALYSIS OF HUMAN T-CELL ANTIGENS. L CYTOGENETIC AND PHENOTYPIC CHARACTERIZATION OF INTERSPECIES T-CELL LINES;92
7.2.14.1;ABSTRACT;92
7.2.14.2;KEYWORDS;92
7.2.14.3;INTRODUCTION;92
7.2.14.4;MATERIALS AND METHODS;92
7.2.14.5;RESULTS;93
7.2.14.6;DISCUSSION;95
7.2.14.7;ACKNOWLEDGMENTS;95
7.2.14.8;REFERENCES;95
7.2.15;CHAPTER 16. GENETIC ANALYSIS OF HUMAN T-CELL ANTIGENS. II. MAPPING OF THE HUMAN CHROMOSOMES INVOLVED IN THE EXPRESSION OF T10 T-CELL ANTIGEN;96
7.2.15.1;ABSTRACT;96
7.2.15.2;KEYWORDS;96
7.2.15.3;INTRODUCTION;96
7.2.15.4;MATERIAL AND METHODS;96
7.2.15.5;RESULTS;97
7.2.15.6;DISCUSSION;98
7.2.15.7;ACKNOWLEDGMENTS;98
7.2.15.8;REFERENCES;98
7.2.16;CHAPTER 17. GENETIC APPROACH TO THE STUDY OF MULTIFACTORIAL DISEASES;100
7.2.16.1;Conclusions;102
7.2.16.2;REFERENCES;103
7.2.17;CHAPTER 18. RESTRICTION FRAGMENT LENGTH POLYMORPHISMS IN THE APOLIPOPROTEIN E-C1-C2 GENE CLUSTER: ASSOCIATION WITH FAMILIAL DYSBETALIPOPROTEINEMIA;104
7.2.17.1;ABSTRACT;104
7.2.17.2;KEYWORDS;104
7.2.17.3;INTRODUCTION;104
7.2.17.4;MATERIALS AND METHODS;105
7.2.17.5;RESULTS AND DISCUSSION;105
7.2.17.6;ACKNOWLEDGEMENTS;107
7.2.17.7;REFERENCES;107
7.2.18;CHAPTER 19. THE INVOLVEMENT OF APOLIPOPROTEIN B GENE VARIANTS IN THE DETERMINATION OF SERUM CHOLESTEROL LEVELS;110
7.2.18.1;ABSTRACT;110
7.2.18.2;KEYWORDS;110
7.2.18.3;INTRODUCTION;110
7.2.18.4;MATERIALS AND METHODS;110
7.2.18.5;RESULTS;111
7.2.18.6;DISCUSSION;112
7.2.18.7;ACKNOWLEDGEMENTS;113
7.2.18.8;REFERENCES;113
7.2.19;CHAPTER 20. THE RELEVANCE OF THE USE OF SYNTHETIC OLIGONUCLEOTIDES FOR APOLIPOPROTEIN E (apoE) MUTANTS FOR CLINICAL DIAGNOSIS OF HYPERLIPOPROTEINEMIA TYPE III;114
7.2.19.1;ABSTRACT;114
7.2.19.2;KEYWORDS;114
7.2.19.3;INTRODUCTION;114
7.2.19.4;MATERIALS AND METHODS;115
7.2.19.5;RESULTS AND DISCUSSION;115
7.2.19.6;REFERENCES;117
7.2.20;CHAPTER 21. DNA MARKERS LINKED TO DIABETES;118
7.2.20.1;ACKNOWLEDGEMENTS;121
7.2.20.2;REFERENCES;121
7.2.21;CHAPTER 22. HLA CLASS II REGION a CHAIN POLYMORPHISM AND THE GENETIC SUSCEPTIBILITY TO INSULIN DEPENDENT (TYPE1) DIABETES MELLITUS AND COELIAC DISEASE;122
7.2.21.1;ABSTRACT;122
7.2.21.2;KEY WORDS;122
7.2.21.3;INTRODUCTION;122
7.2.21.4;DR = GENE;123
7.2.21.5;DQ = /DX = GENES;123
7.2.21.6;DP GENES;124
7.2.21.7;CONCLUSIONS;124
7.2.21.8;ACKNOWLEDGEMENTS;124
7.2.21.9;REFERENCES;124
7.2.22;CHAPTER 23. CORRELATION BETWEEN POLYMORPHIC DNA HAPLOTYPES AT THE PHENYLALANINE HYDROXYLASE LOCUS AND CLINICAL PHENOTYPES OF PHENYLKETONURIA;126
7.2.22.1;ABSTRACT;126
7.2.22.2;INTRODUCTION;126
7.2.22.3;MATERIAL AND METHODS;127
7.2.22.4;RESULTS;127
7.2.22.5;DISCUSSION;129
7.2.23;CHAPTER 24. FURTHER CHARACTERIZATION OF TWO 3H-NEUROTENSIN BINDING SITES IN RAT BRAIN;130
7.2.23.1;INTRODUCTION;130
7.2.23.2;MATERIALS AND METHODS;130
7.2.23.3;RESULTS;130
7.2.23.4;DISCUSSION;132
7.2.23.5;ACKNOWLEDGEMENT;132
7.2.23.6;REFERENCES;132
7.2.24;CHAPTER 25. BIOCHEMICAL AND CELLULAR CHARACTERISATION OF MULTIPLE TACHYKININ RECEPTORS;134
7.2.24.1;ABSTRACT;134
7.2.24.2;KEYWORDS;134
7.2.24.3;INTRODUCTION;134
7.2.24.4;A CELLULAR MODEL FOR SUBSTANCE P RECEPTOR MECHANISMS;135
7.2.24.5;SOLUBILISATION OF SUBSTANCE P BINDING SITES;136
7.2.24.6;CONCLUSION;136
7.2.24.7;REFERENCES;137
7.2.25;CHAPTER 26. REGULATION OF µ-OPIATE RECEPTORS IN CULTURED NEURONS;138
7.2.25.1;ABSTRACT;138
7.2.25.2;KEYWORDS;138
7.2.25.3;INTRODUCTION;138
7.2.25.4;MATERIAL AND METHODS;138
7.2.25.5;RESULTS;139
7.2.25.6;CONCLUSION;141
7.2.25.7;REFERENCES;141
7.3;SECTION B. RECEPTORS;142
7.3.1;CHAPTER 27. 3H-LOFENTANIL BINDING TO OPIATE RECEPTORS IN HUMAN CEREBELLUM;142
7.3.1.1;ABSTRACT;142
7.3.1.2;KEYWORDS;142
7.3.1.3;INTRODUCTION;142
7.3.1.4;MATERIALS AND METHODS;142
7.3.1.5;RESULTS;143
7.3.1.6;CONCLUSION;143
7.3.1.7;REFERENCES;144
7.3.2;CHAPTER 28. DISTRIBUTION IN THE BRAIN AND SPINAL CORD (RAT AND HUMAN) OF ENKEPHALIN TARGETS (µ, d OPIOID RECEPTORS AND ENKEPHALINASE) IN VARIOUS PHYSIOPATHOLOGICAL CONDITIONS;146
7.3.2.1;ABSTRACT;146
7.3.2.2;KEY WORDS;146
7.3.2.3;INTRODUCTION;146
7.3.2.4;METHODS;146
7.3.2.5;RESULTS AND DISCUSSION;147
7.3.2.6;CONCLUSION;148
7.3.2.7;ACKNOWLEDGMENTS;148
7.3.2.8;REFERENCES;148
7.3.3;CHAPTER 29. CHOLECYSTOKININ (CCK) RECEPTORS AND IMMUNOREACTIVITY IN THE RAT BRAIN: FUNCTIONAL SIGNIFICANCE OF SUBREGIONAL DISTRIBUTIONS;150
7.3.3.1;ABSTRACT;150
7.3.3.2;KEY WORDS;150
7.3.3.3;INTRODUCTION;150
7.3.3.4;MATERIAL AND METHODS;150
7.3.3.5;RESULTS AND DISCUSSION;151
7.3.3.6;CONCLUSION;153
7.3.3.7;ACKNOWLEDGMENTS;153
7.3.3.8;REFERENCES;153
7.3.4;CHAPTER 30. MODULATION OF INTRACRANIAL SELF STIMULATION BY CHOLECYSTOKININ DEPENDS ON THE SITE OF ADMINISTRATION;154
7.3.4.1;ABSTRACT;154
7.3.4.2;KEY WORDS;154
7.3.4.3;INTRODUCTION;154
7.3.4.4;NEURQANATCMY OF CHOLECYSTOKININ AND INTRACRANIAL SELF STIMULATION PARADIGM;155
7.3.4.5;CHOLECYSTOKENIN ADMINISTRATTCN ÄND INTRACRANIAL SELF STIMULATION PARADIGM;156
7.3.4.6;ACKNOWLEDGEMENTS;157
7.3.4.7;REFERENCES;157
7.3.5;CHAPTER 31. MODULATION OF NATURAL KILLER (NK) CELL ACTIVITY BY MET-ENKEPHALIN IN CULTURE;158
7.3.5.1;ABSTRACT;158
7.3.5.2;KEYWORDS;158
7.3.5.3;INTRODUCTION;158
7.3.5.4;MATERIALS AND METHODS;158
7.3.5.5;RESULTS;159
7.3.5.6;DISCUSSION;159
7.3.5.7;ACKNOWLEDGEMENT;161
7.3.5.8;REFERENCES;161
7.3.6;CHAPTER 32. AUTORADIOGRAPHIC LOCALIZA TION OF CCK BINDING SITES IN THE HUMAN BRAIN;162
7.3.6.1;ABSTRACT;162
7.3.6.2;KEY WORDS;162
7.3.6.3;INTRODUCTION;162
7.3.6.4;MATERIAL AND METHODS;163
7.3.6.5;RESULTS;163
7.3.6.6;DISCUSSION;164
7.3.6.7;REFERENCES;165
7.3.7;CHAPTER 33. CHARACTERIZATION OF SUBSTANCE P (1-7) GENERATING ENZYME IN HUMAN CHOROID PLEXUS;166
7.3.7.1;ABSTRACT;166
7.3.7.2;KEYWORDS;166
7.3.7.3;INTRODUCTION;166
7.3.7.4;MATERIALS AND METHODS;166
7.3.7.5;RESULTS;167
7.3.7.6;DISCUSSION;169
7.3.7.7;ACKNOWLEDGEMENT;169
7.3.7.8;REFERENCES;169
7.3.8;CHAPTER 34. SOLUBILISATION OF THE MUSCARINIC RECEPTOR IN CHAPSO: A COMPARISON WITH THE RECEPTOR IN MEMBRANES AND IN DIGITONIN SOLUTION;170
7.3.8.1;ABSTRACT;170
7.3.8.2;KEYWORDS;170
7.3.8.3;INTRODUCTION;170
7.3.8.4;METHODS;171
7.3.8.5;RESULTS;172
7.3.8.6;DISCUSSION;173
7.3.8.7;ACKNOWLEDGEMENTS;173
7.3.8.8;REFERENCES;173
7.3.9;CHAPTER 35. ANTI-IDIOTYPIC ANTIBODIES THAT BIND CHOLINERGIC LIGANDS ISOLATED FROM A MYASTHENIA GRAVIS PATIENT;174
7.3.9.1;ABSTRACT;174
7.3.9.2;KEYWORDS;174
7.3.9.3;INTRODUCTION;174
7.3.9.4;MATERIALS AND METHODS;174
7.3.9.5;RESULTS;175
7.3.9.6;CONCLUSIONS;177
7.3.9.7;REFERENCES;177
7.3.10;CHAPTER 36. CELLULAR RESPONSE TO ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS;178
7.3.10.1;ABSTRACT;178
7.3.10.2;KEYWORDS;178
7.3.10.3;INTRODUCTION;178
7.3.10.4;MATERIALS AND METHODS;178
7.3.10.5;RESULTS;179
7.3.10.6;CONCLUSION;181
7.3.10.7;REFERENCES;181
7.3.11;CHAPTER 37. DEGRADATION OF LEU- AND METENKEPHALIN AND THEIR C-TERMINAL EXTENSIONS BY TRIPEPTIDYL PEPTIDASE II;182
7.3.11.1;ABSTRACT;182
7.3.11.2;KEYWORDS;182
7.3.11.3;INTRODUCTION;182
7.3.11.4;MATERIALS AND METHODS;183
7.3.11.5;RESULTS;183
7.3.11.6;DISCUSSION;185
7.3.11.7;ACKNOWLEDGEMENTS;185
7.3.11.8;REFERENCES;185
7.3.12;CHAPTER 38. STRUCTURE AND FUNCTION OF GPIb, THE PRINCIPAL PLATELET VON WILLEBRAND RECEPTOR;186
7.3.12.1;ABSTRACT;186
7.3.12.2;KEY WORDS;186
7.3.12.3;INTRODUCTION;186
7.3.12.4;STRUCTURE OF GPIb;187
7.3.12.5;FUNCTION OF GPIb;188
7.3.12.6;REFERENCES;189
7.3.13;CHAPTER 39. SECRETION OF ir-ACTH BY CELLS OF LYMPHOID ORIGIN: DETECTION AT THE SINGLE CELL LEVEL;190
7.3.13.1;ABSTRACT;190
7.3.13.2;KEYWORDS;190
7.3.13.3;INTRODUCTION;190
7.3.13.4;MATERIALS AND METHODS;190
7.3.13.5;RESULTS;191
7.3.13.6;CONCLUSION;192
7.3.13.7;References;193
7.3.14;CHAPTER 40. CYTOTOXIC ACTIVITY OF LYMPHOCYTE CLONES FROM AGED PEOPLE;194
7.3.14.1;ABSTRACT;194
7.3.14.2;KEYWORDS;194
7.3.14.3;INTRODUCTION;194
7.3.14.4;MATERIAL AND METHODS;195
7.3.14.5;RESULTS;196
7.3.14.6;CONCLUSION;196
7.3.14.7;ACKNOWLEDGEMENTS;197
7.3.14.8;REFERENCES;197
7.3.15;CHAPTER 41. PROLIFERATIVE CAPACITY OF LYMPHOCYTE CLONES FROM OLD SUBJECTS;198
7.3.15.1;ABSTRACT;198
7.3.15.2;KEYWORDS;198
7.3.15.3;INTRODUCTION;198
7.3.15.4;MATERIAL AND METHODS;199
7.3.15.5;RESULTS;200
7.3.15.6;CONCLUSION;201
7.3.15.7;ACKNOWLEDGEMENTS;201
7.3.15.8;REFERENCES;201
7.3.16;CHAPTER 42. MODULATION OF TARGET MOLECULES BY .-INTERFERON: SUSCEPTIBILITY OF LYSIS BY NK CELLS;202
7.3.16.1;ABSTRACT;202
7.3.16.2;KEY WORDS;202
7.3.16.3;INTRODUCTION;202
7.3.16.4;MATERIALS AND METHODS;202
7.3.16.5;RESULTS AND DISCUSSION;203
7.3.16.6;ACKNOWLEDGEMENTS;205
7.3.16.7;REFERENCES;205
7.3.17;CHAPTER 43. LAMININ PRODUCTION BY NATURAL KILLER CELLS;206
7.3.17.1;ABSTRACT;206
7.3.17.2;KEYWORDS;206
7.3.17.3;INTRODUCTION;206
7.3.17.4;MATERIALS AND METHODS;206
7.3.17.5;RESULTS AND CONCLUSIONS;207
7.3.17.6;ACKNOWLEDGEMENTS;209
7.3.17.7;REFERENCES;209
7.3.18;CHAPTER 44. AGONIST FUNCTION OF ANTI-CD2 AND ANTI-CD16 MONOCLONAL ANTIBODIES ON HUMAN NK KILLING;210
7.3.18.1;ABSTRACT;210
7.3.18.2;KEYWORDS;210
7.3.18.3;INTRODUCTION;210
7.3.18.4;MATERIAL AND METHODS;211
7.3.18.5;RESULTS;211
7.3.18.6;DISCUSSION;211
7.3.18.7;ACKNOWLEDGEMENTS;213
7.3.18.8;REFERENCES;213
7.3.19;CHAPTER 45. FLOW CYTOMETRIC EVALUATION OF NATURAL KILLER CYTOTOXICITY;214
7.3.19.1;ABSTRACT;214
7.3.19.2;KEYWORDS;214
7.3.19.3;INTRODUCTION;214
7.3.19.4;MATERIALS AND METHODS;214
7.3.19.5;RESULTS;216
7.3.19.6;CONCLUSION;217
7.3.19.7;ACKNOWLEDGEMENTS;217
7.3.19.8;REFERENCES;217
7.3.20;CHAPTER 46. FREEZE-FRACTURE ULTRASTRUCTURE OF THE BINDING BETWEEN NK LYMPHOCYTE AND K562 TARGET CELLS;218
7.3.20.1;ABSTRACT;218
7.3.20.2;KEY WORDS;218
7.3.20.3;INTRODUCTION;218
7.3.20.4;MATERIALS AND METHODS;219
7.3.20.5;RESULTS;219
7.3.20.6;DISCUSSION;220
7.3.20.7;ACKNOWLEDGMENTS;222
7.3.20.8;REFERENCES;222
7.3.21;CHAPTER 47. THE LOW-AFFINITY Fc RECEPTOR FOR IgG RECOGNIZED BY MOAB AB8.28 IS CAPABLE OF TRANSDUCING ACTIVATION AND DEGRANULATORY SIGNALS IN LARGE GRANULAR LYMPHOCYTES;224
7.3.21.1;ABSTRACT;224
7.3.21.2;KEY WORDS;224
7.3.21.3;INTRODUCTION;224
7.3.21.4;RESULTS and DISCUSSION;225
7.3.21.5;APPLICATIONS;226
7.3.21.6;ACKNOWLEDGMENTS;226
7.3.21.7;REFERENCES;226
7.3.22;CHAPTER 48. BINDING OF C-REACTIVE PROTEIN AND RELATED PEPTIDES TO NEUTROPHILS;228
7.3.22.1;ABSTRACT;228
7.3.22.2;KEYWORDS;228
7.3.22.3;INTRODUCTION;228
7.3.22.4;METHODS;228
7.3.22.5;RESULTS;229
7.3.22.6;DISCUSSION;230
7.3.22.7;REFERENCES;231
7.3.23;CHAPTER 49. THE PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C (PLC) IN RAT NEUTROPHILS (PMN);232
7.3.23.1;ABSTRACT;232
7.3.23.2;KEYWORDS;232
7.3.23.3;INTRODUCTION;232
7.3.23.4;MATERIALS AND METHODS;233
7.3.23.5;RESULTS;233
7.3.23.6;CONCLUSIONS;235
7.3.23.7;ACKNOWLEDGEMENTS;235
7.3.23.8;REFERENCES;235
7.3.24;CHAPTER 50. SUBCELLULAR LOCALIZATION OF Mac-1 (CR3) IN THE HUMAN NEUTROPHIL;236
7.3.24.1;ABSTRACT;236
7.3.24.2;KEY WORDS;236
7.3.24.3;INTRODUCTION;236
7.3.24.4;MATERIALS AND METHODS;236
7.3.24.5;RESULTS;237
7.3.24.6;DISCUSSION;238
7.3.24.7;REFERENCES;239
7.3.25;CHAPTER 51. POLYMORPHONUCLEAR CELL Fc-GAMMA RECEPTORS IN RHEUMATOID ARTHRITIS;240
7.3.25.1;ABSTRACT;240
7.3.25.2;KEYWORDS;240
7.3.25.3;INTRODUCTION;240
7.3.25.4;MATERIALS AND METHODS;240
7.3.25.5;RESULTS AND DISCUSSION;242
7.3.25.6;ACKNOWLEDGEMENTS;243
7.3.25.7;REFERENCES;243
7.3.26;CHAPTER 52. FORMYLPEPTIDE INDUCED NEUTROPHIL CHEMOTAXIS INHIBITION BY ATROPINE AND PHENTOLAMINE;244
7.3.26.1;ABSTRACT;244
7.3.26.2;KEYWORDS;244
7.3.26.3;INTRODUCTION;244
7.3.26.4;METHODS;244
7.3.26.5;RESULTS;245
7.3.26.6;DISCUSSION;246
7.3.26.7;REFERENCES;247
7.3.27;CHAPTER 53. RECEPTORS FOR TUFTSIN ON PLASMA MEMBRANES OF MACROPHAGES AND MACROPHAGE HYBRIDOMA CELL LINES;248
7.3.27.1;ABSTRACT;248
7.3.27.2;KEYWORDS;248
7.3.27.3;INTRODUCTION;248
7.3.27.4;MATERIALS AND METHODS;248
7.3.27.5;RESULTS;249
7.3.27.6;DISCUSSION;251
7.3.27.7;REFERENCES;251
7.3.28;CHAPTER 54. ANALYSIS OF CELL MEDIATED IMMUNE RESPONSE BY USING INTERSPECIES HYBRID LINES AS STIMULATOR;252
7.3.28.1;ABSTRACT;252
7.3.28.2;KEYWORDS;252
7.3.28.3;INTRODUCTION;252
7.3.28.4;MATERIALS AND METHODS;252
7.3.28.5;RESULTS;253
7.3.28.6;DISCUSSION;255
7.3.28.7;ACKNOWLEDGEMENTS;255
7.3.28.8;REFERENCES;256
7.3.29;CHAPTER 55. THE PURIFICATION OF HUMAN a1-T GLYCOPROTEIN FROM SERUM AND ITS CLINICAL APPLICATION;258
7.3.29.1;ABSTRACT;258
7.3.29.2;KEYWORDS;258
7.3.29.3;INTRODUCTION;258
7.3.29.4;MATERIALS AND METHODS;258
7.3.29.5;RESULTS;259
7.3.29.6;DISCUSSION;261
7.3.29.7;REFERENCES;261
7.3.30;CHAPTER 56. ROLE OF FIBRONECTIN IN THE FUNCTION OF NEUTROPHILS;262
7.3.30.1;ABSTRACT;262
7.3.30.2;KEY WORDS;262
7.3.30.3;INTRODUCTION;262
7.3.30.4;PATIENTS;263
7.3.30.5;MATERIALS AND METHODS;263
7.3.30.6;RESULTS;263
7.3.30.7;CONCLUSION;265
7.3.30.8;ACKNOWLEDGEMENT;265
7.3.30.9;REFERENCES;265
7.3.31;CHAPTER 57. STUDIES ON GROWTH HORMONE RECEPTORS;266
7.3.31.1;ABSTRACT;266
7.3.31.2;KEYWORDS;266
7.3.31.3;INTRODUCTION;266
7.3.31.4;MATERIALS AND METHODS;266
7.3.31.5;RESULTS AND DISCUSSION;267
7.3.31.6;ACKNOWLEDGEMENTS;269
7.3.31.7;REFERENCES;269
7.3.32;CHAPTER 58. CHARACTERIZATION OF THE SOMATOGENIC RECEPTOR IN RAT LIVER;270
7.3.32.1;ABSTRACT;270
7.3.32.2;KEYWORDS;270
7.3.32.3;INTRODUCTION;270
7.3.32.4;MATERIALS AND METHODS;271
7.3.32.5;RESULTS;271
7.3.32.6;CONCLUSION;272
7.3.32.7;REFERENCES;273
7.3.33;CHAPTER 59. CHARACTERIZATION OF RAT LIVER PROLACTIN RECEPTOR;274
7.3.33.1;ABSTRACT;274
7.3.33.2;KEYWORDS;274
7.3.33.3;INTRODUCTION;274
7.3.33.4;MATERIALS AND METHODS;274
7.3.33.5;RESULTS;275
7.3.33.6;CONCLUSIONS;277
7.3.33.7;REFERENCES;277
7.3.34;CHAPTER 60. CHARACTERIZATION OF ANGIOTENSIN RECEPTORS FROM HUMAN KIDNEY;278
7.3.34.1;ABSTRACT;278
7.3.34.2;KEYWORDS;278
7.3.34.3;INTRODUCTION;278
7.3.34.4;MATERIAL AND METHODS;279
7.3.34.5;RESULTS AND DISCUSSION;279
7.3.34.6;ACKNOWLEGEMENT;281
7.3.34.7;REFERENCES;281
7.3.35;CHAPTER 61. INSULIN BINDING ON ERYTHROCYTES IS INCREASED BY ALBUMIN-ASSOCIATED PLASMA MODULATORS;282
7.3.35.1;ABSTRACT;282
7.3.35.2;INTRODUCTION;282
7.3.35.3;MATERIALS AND METHODS;282
7.3.35.4;RESULTS;283
7.3.35.5;DISCUSSION;283
7.3.35.6;AKNOWLEDGEMENTS;284
7.3.35.7;REFERENCES;284
7.3.36;CHAPTER 62. INSULIN LIKE GROWTH FACTOR 1 RECEPTOR ON ISOLATED LYMPHOCYTES AS A BASIS FOR STUDIES OF IFG-1 RECEPTORS ON MITOGEN-STIMULATED-LYMPHOCYTES AND LYMPHATIC CELLS;286
7.3.36.1;ABSTRACT;286
7.3.36.2;KEYWORDS;286
7.3.36.3;INTRODUCTION;286
7.3.36.4;RESULTS;287
7.3.36.5;REFERENCES;290
7.3.37;CHAPTER 63. WHICH METHOD FOR "MICROALBUMINURIA" IN DIABETES MELLITUS?;292
7.3.37.1;ABSTRACT;292
7.3.37.2;KEYWORDS;292
7.3.37.3;INTRODUCTION;292
7.3.37.4;MATERIALS AND METHODS;292
7.3.37.5;RESULTS;293
7.3.37.6;DISCUSSION;294
7.3.37.7;CONCLUSION;294
7.3.37.8;REFERENCES;294
7.3.38;CHAPTER 64. HETEROGENEITY OF OESTROGEN RECEPTORS IN HUMAN BREAST TUMOURS;296
7.3.38.1;ABSTRACT;296
7.3.38.2;KEYWORDS;296
7.3.38.3;INTRODUCTION;296
7.3.38.4;MATERIALS AND METHODS;296
7.3.38.5;RESULTS;297
7.3.38.6;DISCUSSION;298
7.3.38.7;ACKNOWLEDGEMENTS;299
7.3.38.8;REFERENCES;299
7.3.39;CHAPTER 65. CLINICAL SIGNIFICANCE OF ABNORMAL OESTROGEN RECEPTORS IN BREAST AND GYNAECOLOGICAL CANCERS;300
7.3.39.1;ABSTRACT;300
7.3.39.2;KEYWORDS;300
7.3.39.3;INTRODUCTION;300
7.3.39.4;CONCLUSION;303
7.3.39.5;ACKNOWLEDGEMENTS;303
7.3.39.6;REFERENCES;303
7.3.40;CHAPTER 66. ARE EPIDERMAL GROWTH FACTOR RECEPTORS PRESENT IN THE HUMAN PROSTATE;304
7.3.40.1;ABSTRACT;304
7.3.40.2;KEYWORDS;304
7.3.40.3;INTRODUCTION;304
7.3.40.4;MATERIALS AND METHODS;305
7.3.40.5;RESULTS;305
7.3.40.6;DISCUSSION;306
7.3.40.7;ACKNOWLEDGEMENTS;307
7.3.40.8;REFERENCES;307
7.3.41;CHAPTER 67. ANTIPROTE ASIC PEPTIDES IN HUMAN CANCER: A HOST REACTION OR AN AUTONOMIC SECRETION;308
7.3.41.1;ABSTRACT;308
7.3.41.2;KEYWORDS;308
7.3.41.3;INTRODUCTION;308
7.3.41.4;MATERIAL AND METHODS;308
7.3.41.5;RESULTS;308
7.3.41.6;COMMENTS;309
7.3.41.7;REFERENCES;311
7.3.42;CHAPTER 68. BIOLOGICAL EXPRESSION OF PROTEINASE INHIBITORS PATTERN IN HUMAN CANCER. THE CLINICAL POTENTIAL UTILITY;312
7.3.42.1;ABSTRACT;312
7.3.42.2;KEYWORDS;312
7.3.42.3;INTRODUCTION;312
7.3.42.4;MATERIAL AND METHODS;312
7.3.42.5;RESULTS;312
7.3.42.6;COMMENTS;314
7.3.42.7;REFERENCES;315
7.3.43;CHAPTER 69. SECRETION OF TWO DIFFERENT TYPES OF GROWTH FACTORS BY THE HT-29 HUMAN COLONIC ADENOCARCINOMA CELL LINE;316
7.3.43.1;INTRODUCTION;316
7.3.43.2;KEYWORDS;316
7.3.43.3;MATERIALS AND METHODS;316
7.3.43.4;RESULTS;317
7.3.43.5;DISCUSSION;319
7.3.43.6;REFERENCES;319
7.3.44;CHAPTER 70. FIBROBLAST AROMATASE: A NEW SYSTEM FOR INVESTIGATING THE MECHANISMS OF ACTION OF VITAMIN D METABOLITES ON CELLULAR DIFFERENTIATION;320
7.3.44.1;ABSTRACT;320
7.3.44.2;KEYWORDS;320
7.3.44.3;INTRODUCTION;320
7.3.44.4;MATERIALS AND METHODS;321
7.3.44.5;RESULTS;321
7.3.44.6;DISCUSSION;322
7.3.44.7;ACKNOWLEDGEMENTS;323
7.3.44.8;REFERENCES;323
7.3.45;CHAPTER 71. COMPARISON OF PROSTATE SPECIFIC ANTIGEN AND PROSTATIC ACID PHOSPHATASE IN THE DETECTION OF PROSTATIC CANCER;324
7.3.45.1;ABSTRACT;324
7.3.45.2;KEYWORDS;324
7.3.45.3;INTRODUCTION;324
7.3.45.4;MATERIALS AND METHODS;325
7.3.45.5;RESULTS;325
7.3.45.6;DISCUSSION;326
7.3.45.7;REFERENCE;327
7.3.46;CHAPTER 72. BEHAVIOUR OF SERUM ANTIPROTEASIC ENZYMES IN RELATION WITH CHEMOTHERAPY REGIMENS;328
7.3.46.1;ABSTRACT;328
7.3.46.2;KEYWORDS;328
7.3.46.3;INTRODUCTION;328
7.3.46.4;MATERIAL AND METHODS;328
7.3.46.5;RESULTS;329
7.3.46.6;COMMENTS;330
7.3.46.7;REFERENCES;331
7.3.47;CHAPTER 73. EFFECT OF TUMOR'S METASTATIC POTENTIAL AND GROWTH RATE ON TUMOR/HOST RELATIONSHIP;332
7.3.47.1;ABSTRACT;332
7.3.47.2;KEYWORDS;332
7.3.47.3;INTRODUCTION;332
7.3.47.4;MATERIALS AND METHOD;332
7.3.47.5;RESULTS;333
7.3.47.6;DISCUSSION;334
7.3.47.7;REFERENCES;335
7.3.48;CHAPTER 74. THE UTILIZATION OF MONOCLONAL ANTIBODIES TO DETECT ALTERATIONS IN LEUKOCYTIC SUBSET RATIOS FOLLOWING CHEMOTHERAPY;336
7.3.48.1;ABSTRACT;336
7.3.48.2;KEY WORDS;336
7.3.48.3;INTRODUCTION;336
7.3.48.4;MATERIALS AND METHODS;337
7.3.48.5;RESULTS;338
7.3.48.6;DISCUSSION;339
7.3.48.7;REFERENCES;339
7.3.49;CHAPTER 75. EFFECT OF TUMOR NECROSIS FACTOR ON A PROSTATE TUMOR MODEL;340
7.3.49.1;ABSTRACT;340
7.3.49.2;INTRODUCTION;340
7.3.49.3;MATERIALS AND METHODS;341
7.3.49.4;IMPLANTATION OF TUMORS;341
7.3.49.5;EXPRESSION OF DATA AND STATISTICAL ANALYSIS;341
7.3.49.6;THERAPY;341
7.3.49.7;RESULTS;341
7.3.49.8;DISCUSSION;342
7.3.49.9;ACKNOWLEDGEMENTS;343
7.3.49.10;REFERENCES:;343
7.3.50;CHAPTER 76. EVALUATION OF ADRIAMYCIN CHEMOTHERAPY AND POLYAMINE SYNTHESIS INHIBITOR ALPHA-DIFLUOROMETHYL- ORNITHINE (DFMO) IN THE TREATMENT OF A TRANSPLANTABLE PROSTATE CARCINOMA OF THE RAT;344
7.3.50.1;ABSTRACT;344
7.3.50.2;KEY WORDS;344
7.3.50.3;INTRODUCTION;344
7.3.50.4;MATERIALS AND METHODS;345
7.3.50.5;RESULTS;345
7.3.50.6;DISCUSSION;347
7.3.50.7;ACKNOWLEDGEMENTS;347
7.3.50.8;REFERENCES;347
7.3.51;CHAPTER 77. SERUM LEVELS OF FREE AND LIGAND-BOUND RECEPTOR FOR POLYMERIC IMMUNOGLOBULINS IN BILE DUCT-LIGATED RATS;348
7.3.51.1;ABSTRACT;348
7.3.51.2;KEYWORDS;348
7.3.51.3;INTRODUCTION;348
7.3.51.4;MATERIALS AND METHODS;349
7.3.51.5;RESULTS;349
7.3.51.6;DISCUSSION;350
7.3.51.7;ACKNOWLEDGEMENTS;351
7.3.51.8;REFERENCES;351
7.3.52;CHAPTER 78. IMMUNOGLOBULIN (IG) RECEPTORS OF RENAL TUBULE: SUBCELLULAR LOCALIZATION AND CHARACTERIZATION;352
7.3.52.1;SUMMARY;352
7.3.52.2;KEY WORDS;352
7.3.52.3;INTRODUCTION;352
7.3.52.4;MATERIAL AND METHODS;353
7.3.52.5;RESULTS and DISCUSSION;353
7.3.52.6;ACKNOWLEDGEMENT;355
7.3.52.7;REFERENCES;355
7.3.53;CHAPTER 79. A MONOCLONAL ANTIBODY INTERACTING WITH HUMAN Fe. RECEPTOR;356
7.3.53.1;ABSTRACT;356
7.3.53.2;KEYWORDS;356
7.3.53.3;INTRODUCTION;356
7.3.53.4;MATERIALS AND METHODS;356
7.3.53.5;RESULTS AND DISCUSSION;357
7.3.53.6;ACKNOWLEDGEMENTS;359
7.3.53.7;REFERENCES;359
7.3.54;CHAPTER 80. HUMAN Fe. EPITOPES AND INTERACTION SITES FOR EFFECTOR MOLECULES;360
7.3.54.1;ABSTRACT;360
7.3.54.2;KEYWORDS;360
7.3.54.3;INTRODUCTION;360
7.3.54.4;MATERIALS AND METHODS;362
7.3.54.5;RESULTS AND DISCUSSION;362
7.3.54.6;ACKNOWLEDGMENT;363
7.3.54.7;REFERENCES;363
7.3.55;CHAPTER 81. OCCURRENCE OF DAMAGED HEAVY CHAINS DURING PURIFICA TION OF MURINE IgE ANTIBODIES BY FAST PROTEIN LIQUID CHROMATOGRAPHY(FPLC) AND THEIR EFFECT ON THE DETERMINATION OF CONCENTRATION AND AFFINITY IN ELISA;364
7.3.55.1;ABSTRACT;364
7.3.55.2;INTRODUCTION;364
7.3.55.3;MATERIALS AND METHODS;365
7.3.55.4;RESULTS;366
7.3.55.5;DISCUSSION;369
7.3.55.6;ACKNOWLEDGEMENTS;371
7.3.55.7;REFERENCES;371
7.3.56;CHAPTER 82. COOPERATION OF KUPFFER CELLS AND PERISINUSOIDAL LIPOCYTES IN THE PRODUCTION OF LIVER BIOMATRIX COMPONENTS: MEDIATORS OF KUPFFER CELLS STIMULATE PROLIFERATION AND PROTEOGLYCAN SYNTHESIS OF LIPOCYTES;372
7.3.56.1;ABSTRACT;372
7.3.56.2;KEYWORDS;372
7.3.56.3;INTRODUCTION;372
7.3.56.4;MATERIALS AND METHODS;372
7.3.56.5;RESULTS;373
7.3.56.6;CONCLUSION;375
7.3.56.7;ACKNOWLEDGEMENT;375
7.3.56.8;REFERENCES;375
7.3.57;CHAPTER 83. INTERACTIONS OF FREE GLYCOSAMINOGLYCAN CHAINS AND OF NATIVE PROTEOGLYCANS SECRETED BY RAT LIVER FAT STORING CELLS WITH HEPATOCYTIC SURFACES;376
7.3.57.1;ABSTRACT;376
7.3.57.2;KEYWORDS;376
7.3.57.3;INTRODUCTION;376
7.3.57.4;MATERIALS AND METHODS;377
7.3.57.5;RESULTS;377
7.3.57.6;CONCLUSION;379
7.3.57.7;ACKNOWLEDGEMENT;379
7.3.57.8;REFERENCES;379
7.3.58;CHAPTER 84. EPITHELIAL CELL SURFACE PROTEOGLYCAN: A MATRIX RECEPTOR FOR INTERSTITIAL COLLAGENS AND FIBRONECTIN;380
7.3.58.1;ABSTRACT;380
7.3.58.2;KEYWORDS;380
7.3.58.3;INTRODUCTION;380
7.3.58.4;EPITHELIAL CELL SURFACE HEPARAN SULFATE-RICH PROTEOGLYCAN;381
7.3.58.5;PROTEOGLYCAN BINDS NMuMG CELLS TO INTERSTITIAL COLLAGENS AND FIBRONECTIN;381
7.3.58.6;PROTEOGLYCAN LINKS EPITHELIAL CYTOSKELETON TO MATRIX;381
7.3.58.7;PROTEOGLYCAN IS SHED BY CLEAVAGE OF ITS ECTODOMAIN FROM ITS MEMBRANE-ASSOCIATED DOMAIN;381
7.3.58.8;SIGNIFICANCE OF PROTEOGLYCAN-MEDIATED MATRIX ANCHORAGE;382
7.3.58.9;ACKNOWLEDGEMENTS;382
7.3.58.10;REFERENCES;382
7.3.59;CHAPTER 85. PROPERTIES OF HIGH AND LOW MOLECULAR WEIGHT PHOSPHOMANNOSE RECEPTORS FROM BOVINE LIVER AND TESTIS;384
7.3.59.1;ABSTRACT;384
7.3.59.2;KEY WORDS;384
7.3.59.3;INTRODUCTION;384
7.3.59.4;RESULTS AND DISCUSSION;385
7.3.59.5;CONCLUSION;386
7.3.59.6;REFERENCES;386
7.3.60;CHAPTER 86. FIBRINOGEN BINDING ON CANDIDA ALBICANS GERM TUBES AND MYCELIUM;388
7.3.60.1;ABSTRACT;388
7.3.60.2;KEYWORDS;388
7.3.60.3;INTRODUCTION;388
7.3.60.4;MATERIAL AND METHODS;389
7.3.60.5;RESULTS AND DISCUSSION;389
7.3.60.6;ACKNOWLEDGEMENTS;391
7.3.60.7;REFERENCES;391
7.3.61;CHAPTER 87. RECEPTOR-MEDIATED UPTAKE OF GLUCURONIDASE INTO GLIAL CELLS FROM RAT BRAIN;392
7.3.61.1;ABSTRACT;392
7.3.61.2;KEYWORDS;392
7.3.61.3;INTRODUCTION;392
7.3.61.4;MATERIALS AND METHODS;392
7.3.61.5;RESULTS;393
7.3.61.6;DISCUSSION;394
7.3.61.7;CONCLUSIONS;394
7.3.61.8;ACKNOWLEDGEMENTS;394
7.3.61.9;REFERENCES;394
7.3.62;CHAPTER 88. CELL FUSION IN ELECTRIC FIELD IN THE PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST SOLUBLE AND CELLULAR POLYPEPTIDE ANTIGENS;396
7.3.62.1;ABSTRACT;396
7.3.62.2;KEYWORDS;396
7.3.62.3;INTRODUCTION;396
7.3.62.4;MATERIALS AND METHODS;396
7.3.62.5;RESULTS AN DISCUSSION;397
7.3.62.6;ACKNOWLEDGEMENTS;398
7.3.62.7;REFERENCES;398
7.3.63;CHAPTER 89. TYPE IX AND TYPE XII COLLAGENS: A NEW CLASS OF EXTRACELLULAR MATRIX COMPONENTS;400
7.3.63.1;ABSTRACT;400
7.3.63.2;KEYWORDS;400
7.3.63.3;INTRODUCTION;400
7.3.63.4;MATERIALS AND METHODS;401
7.3.63.5;RESULTS AND DISCUSSION;401
7.3.63.6;ACKNOWLEDGEMENTS;403
7.3.63.7;REFERENCES;403
7.3.64;CHAPTER 90. THE USE OF SPECIFIC ANTISERA TO STUDY THE DEVELOPMENTAL REGULATION OF GUANINE NUCLEOTIDE BINDING PROTEINS;404
7.3.64.1;ABSTRACT;404
7.3.64.2;KEYWORDS;404
7.3.64.3;INTRODUCTION;404
7.3.64.4;RESULTS AND DISCUSSION;405
7.3.65;CHAPTER 91. IDENTIFICATION OF BRADYKININ RECEPTORS ON NG108-15 HYBRID CELLS;408
7.3.65.1;ABSTRACT;408
7.3.65.2;KEYWORDS;408
7.3.65.3;INTRODUCTION;408
7.3.65.4;MATERIALS AND METHODS;408
7.3.65.5;RESULTS AND DISCUSSION;409
7.3.65.6;CONCLUSIONS;411
7.3.65.7;ACKNOWLEDGEMENTS;411
7.3.65.8;REFERENCES;411
7.4;SECTION C: Conformation and Function of Biologically Active Peptides;412
7.4.1;CHAPTER 92. THE USE OF MOLECULAR GRAPHICS IN THE DESIGN OF INHIBITORS OF ZINC PROTEASES;414
7.4.1.1;ABSTRACT;414
7.4.1.2;KEYWORDS;414
7.4.1.3;REFERENCES;417
7.4.2;CHAPTER 93. NEW TECHNIQUES FOR THE EXPLORATION OF MOLECULAR ENERGY SURFACES AND THEIR APPLICATION TO DERMORPHIN;418
7.4.2.1;ABSTRACT;418
7.4.2.2;KEYWORDS;418
7.4.2.3;INTRODUCTION;418
7.4.2.4;COMPUTATIONAL METHODS;419
7.4.2.5;RESULTS;419
7.4.2.6;CONCLUDING REMARKS;420
7.4.2.7;ACKNOWLEDGEMENTS;420
7.4.2.8;REFERENCES;420
7.4.3;CHAPTER 94. TWO-DIMENSIONAL EXCHANGE EXPERIMENTS IN NMR STUDIES OF PROTEIN DYNAMICS AND FOLDING;422
7.4.3.1;ABSTRACT;422
7.4.3.2;KEYWORDS;422
7.4.3.3;INTRODUCTION;422
7.4.3.4;MATERIALS AND METHODS;423
7.4.3.5;RESULTS AND DISCUSSION;423
7.4.3.6;ACKNOWLEDGEMENTS;425
7.4.3.7;REFERENCES;425
7.4.4;CHAPTER 95. PROPERTIES OF THE PROTEIN SOLVENT INTERFACE, STUDIED BY DEUTERIUM EXCHANGE IN BASIC PANCREATIC TRYPSIN INHIBITOR;426
7.4.4.1;ABSTRACT;426
7.4.4.2;KEYWORDS;426
7.4.4.3;INTRODUCTION;426
7.4.4.4;EXPERIMENTAL;427
7.4.4.5;RESULTS;427
7.4.4.6;DISCUSSION;428
7.4.4.7;ACKNOWLEDGEMENTS;429
7.4.4.8;REFERENCES;429
7.4.5;CHAPTER 96. A COMPARATIVE MOLECULAR STRUCTURAL STUDY OF THE THIRD COMPONENT OF COMPLEMENT AND ALPHA -2-MACROGLOBULIN: STRUCTURES OF THE PEPTIDE SEGMENTS THAT ARE SUSCEPTIBLE TO THE ATTACK BY ENDOPROTEINASES;430
7.4.5.1;ABSTRACT;430
7.4.5.2;KEYWORDS;430
7.4.5.3;INTRODUCTION;430
7.4.5.4;MATERIALS AND METHODS;431
7.4.5.5;RESULTS AND DISCUSSION;431
7.4.5.6;REFERENCES;436
7.4.6;CHAPTER 97. DYNAMICS OF ELASTASE PEPTIDE COMPLEXES. A 13C NMR STUDY;438
7.4.6.1;ABSTRACT;438
7.4.6.2;KEYWORDS;438
7.4.6.3;INTRODUCTION;438
7.4.6.4;MATERIALS AND METHODS;438
7.4.6.5;RESULTS AND DISCUSSION;440
7.4.6.6;CONCLUSION;441
7.4.6.7;REFERENCE;441
7.4.7;CHAPTER 98. THE DETERMINATION OF THE THREE DIMENSIONAL STRUCTURE OF HUMAN EPIDERMAL GROWTH FACTOR FROM 1H-NMR DATA;442
7.4.7.1;Results and Discussion;443
7.4.7.2;Summary;445
7.4.7.3;References;445
7.4.8;CHAPTER 99. CONFORMATIONAL COMPARISON OF FOUR CONSTRAINED STEROISOMERIC CYCLIC ENKEPHALIN ANALOGS BY 1H NMR AND COMPUTER SIMULATIONS;446
7.4.8.1;ABSTRACT;446
7.4.8.2;INTRODUCTION;446
7.4.8.3;MATERIALS AND METHODS;447
7.4.8.4;RESULTS AND DISCUSSION;447
7.4.8.5;ACKNOWLEDGMENT;449
7.4.8.6;REFERENCES;449
7.4.9;CHAPTER 100. OPIOID PEPTIDES IN MICELLAR SYSTEMS: CONFORMATIONAL ANALYSIS BY 1D AND 2D 1H-NMR AND CIRCULAR DICHROISM;450
7.4.9.1;ABSTRACT;450
7.4.9.2;INTRODUCTION;450
7.4.9.3;MATERIAL AND METHODS;450
7.4.9.4;RESULTS AND DISCUSSION;451
7.4.9.5;REFERENCES;453
7.4.10;CHAPTER 101. LONG, CHIRAL POLYPEPTIDE 310-HELICES;454
7.4.10.1;ABSTRACT;454
7.4.10.2;KEYWORDS;454
7.4.10.3;INTRODUCTION;454
7.4.10.4;RESULTS AND DISCUSSION;454
7.4.10.5;CONCLUSION;457
7.4.10.6;REFERENCES;457
7.4.11;CHAPTER 102. USES OF SYNCHROTRON X-RADIATION IN BIOLOGICAL CRYSTALLOGRAPHY;458
7.4.11.1;ABSTRACT;458
7.4.11.2;KEYWORDS;458
7.4.11.3;INTRODUCTION;458
7.4.11.4;ACNOWLEDGEMENTS;461
7.4.11.5;REFERENCES;461
7.4.12;CHAPTER 103. X-RAY CRYSTALLOGRAPHY OF LINEAR PEPTIDES THROUGH THE RENIN-ANGIOTENSIN SYSTEM;462
7.4.12.1;ABSTRACT;462
7.4.12.2;KEYWORDS;462
7.4.12.3;CONCLUSION;465
7.4.12.4;ACKNOWLEDGEMENTS;465
7.4.12.5;REFERENCES;465
7.4.13;CHAPTER 104. IDENTIFICATION OF FOLDED STRUCTURES IN IMMUNOGENIC PEPTIDES BY 2D NMR SPECTROSCOPY;466
7.4.13.1;ABSTRACT;466
7.4.13.2;KEYWORDS;466
7.4.13.3;INTRODUCTION;466
7.4.13.4;MATERIALS AND METHODS;467
7.4.13.5;RESULTS AND DISCUSSION;467
7.4.13.6;CONCLUSIONS;468
7.4.13.7;REFERENCES;469
7.4.14;CHAPTER 105. CONFORMATIONAL PROPERTIES OF CALCITONIN AND THEIR RELATIONSHIP TO BIOLOGICAL ACTIVITY;470
7.4.14.1;ABSTRACT;470
7.4.14.2;KEYWORDS;470
7.4.14.3;INTRODUCTION;470
7.4.14.4;RESULTS AND DISCUSSION;471
7.4.14.5;REFERENCES;473
7.4.15;CHAPTER 106. VOLTAGE-DEPENDENT HELICAL CHANNEL FORMERS: STRUCTURE AND FUNCTION;474
7.4.15.1;ABSTRACT;474
7.4.15.2;KEYWORDS;474
7.4.15.3;INTRODUCTION;474
7.4.15.4;STRUCTURE AND FUNCTION OF ALAMETHICIN LIKE CHANNEL FORMERS;475
7.4.15.5;REFERENCES;477
7.4.16;CHAPTER 107. ON THE DIFFERENCE BETWEEN MOLECULAR CONFORMATION AND HYDROGEN BONDING IN SOLUTION AND IN CRYSTALLINE STATE;478
7.4.17;CHAPTER 108. ANTIPROTEASE ENGINEERING: NEW PROTEASE INHIBITORS FOR THERAPEUTIC USE;482
7.4.17.1;ABSTRACT;482
7.4.17.2;KEYWORDS;482
7.4.17.3;INTRODUCTION;482
7.4.17.4;AN E. COLI PRODUCTION SYSTEM FOR a1 AT VARIANTS;482
7.4.17.5;THE PROPERTIES OF a1 AT VARIANTS;483
7.4.17.6;a1 AT (ALA 357 , ARG 358 ) : A SELECTIVE INHIBITOR OF THE KININ FORMING PATHWAY;483
7.4.17.7;ACKNOWLEDGEMENTS;484
7.4.17.8;REFERENCES;484
7.4.18;CHAPTER 109. ENKEPHALINASE, A METALLOENDO-PEPTIDASE INVOLVED IN THE INACTIVATION OF BIOLOGICALLY ACTIVE PEPTIDES;486
7.4.18.1;ABSTRACT;486
7.4.18.2;KEY WORDS;486
7.4.18.3;INTRODUCTION;486
7.4.18.4;RESULTS AND DISCUSSION;486
7.4.18.5;CONCLUSION;489
7.4.18.6;ACKNOWLEDGEMENTS;489
7.4.18.7;REFERENCES;489
7.4.19;CHAPTER 110. NEUTRON SCATTERING ANALYSIS OF ANGIOTENSIN-CONVERTING ENZYME (ACE);490
7.4.19.1;ABSTRACT;490
7.4.19.2;KEY-WORDS;490
7.4.19.3;INTRODUCTION;490
7.4.19.4;MATERIALS AND METHODS;491
7.4.19.5;RESULTS AND DISCUSSION;493
7.4.19.6;ACKNOWLEDGMENTS;494
7.4.19.7;REFERENCES;494
7.4.20;CHAPTER 111. IMMUNOCHEMICAL STUDY OF CYCLOSPORINE CONFORMATION IN AQUEOUS MEDIUM;496
7.4.20.1;ABSTRACT;496
7.4.20.2;KEYWORDS;496
7.4.20.3;INTRODUCTION;496
7.4.20.4;MATERIALS AND METHODS;497
7.4.20.5;RESULTS;497
7.4.20.6;CONCLUSION;499
7.4.20.7;REFERENCES;499
7.4.21;CHAPTER 112. LOCALIZATION OF TWO EPITOPES WITH MONOCLONAL ANTIBODIES IN THE CELL ATTACHMENT DOMAIN OF FIBRONECTIN BY SYNTHETIC PEPTIDES;500
7.4.21.1;ABSTRACT;500
7.4.21.2;KEYWORDS;500
7.4.21.3;INTRODUCTION;500
7.4.21.4;MATERIALS AND METHODS;500
7.4.21.5;RESULTS AND DISCUSSION;501
7.4.21.6;ACKNOWLEDGEMENTS;503
7.4.21.7;REFERENCES;503
7.4.22;CHAPTER 113. IMMUN ORE ACTIVITY AND BIOLOGICAL ACTIVITY OF THYMULIN ANALOGS STUDIED BY EIA AND ROSETTE ASSAY;504
7.4.22.1;ABSTRACT;504
7.4.22.2;KEY WORDS;504
7.4.22.3;INTRODUCTION;504
7.4.22.4;MATERIAL AND METHODS;505
7.4.22.5;RESULTS AND DISCUSSION;505
7.4.22.6;REFERENCES;507
7.4.23;CHAPTER 114. AFFINITY CONSTANT AND "IN VITRO" BIOLOGICAL ACTIVITY OF HUMAN MONOCLONAL ANTIBODIES AGAINST Rh(D) ANTIGEN;508
7.4.23.1;ABSTRACT;508
7.4.23.2;KEYWORDS;508
7.4.23.3;INTRODUCTION;508
7.4.23.4;MATERIALS AND METHODS;509
7.4.23.5;RESULTS;510
7.4.23.6;DISCUSSION;511
7.4.23.7;REFERENCES;511
7.4.24;CHAPTER 115. CONTIGUOUS AND DISCONTIGUOUS ANTIGENIC DETERMINANTS ON PROTEINS;512
7.4.24.1;ABSTRACT;512
7.4.24.2;INTRODUCTION;512
7.4.24.3;MATERIALS AND METHODS;512
7.4.24.4;RESULTS;513
7.4.24.5;DISCUSSION;514
7.4.24.6;REFERENCES;515
8;AUTHOR INDEX;516
9;SUBJECT INDEX;522